Search for semaglutide in Houston and most of what comes back is clinics and med spas, each quoting its own monthly price. The medicine is the same in all of them, and the manufacturers' cash prices are fixed. What differs is whether you qualify, whether insurance pays, and whether you are being offered an FDA-approved product or a compounded copy.
Below: who semaglutide and tirzepatide are approved for, what they cost without insurance, why many people in Texas end up paying cash, what the FDA says about compounded versions, and the studies open in Houston for people with prediabetes, fatty liver, diabetes or sleep apnea.
Overweight with prediabetes, but your BMI is under 30?
A study of orforglipron, the medicine in the GLP-1 pill Foundayo, is enrolling adults with a BMI of 25 to 29.9 and prediabetes, borderline blood pressure, or borderline cholesterol at a site in Houston. Its use in this group is investigational. People with diabetes, or who took a weight loss medicine in the past six months, are not eligible.
Semaglutide, tirzepatide and the brand names you will see
Semaglutide and tirzepatide are the active ingredients. The brand name tells you what each product is approved for, and that is what insurance looks at.
- Wegovy (semaglutide): weight management, as a weekly injection or a daily pill. It is also approved to lower the risk of heart attack and stroke in adults with heart disease and overweight or obesity, and to treat MASH, a form of fatty liver disease, with moderate to advanced scarring.
- Ozempic (semaglutide): type 2 diabetes.
- Zepbound (tirzepatide): weight management, and moderate to severe obstructive sleep apnea in adults with obesity.
- Mounjaro (tirzepatide): type 2 diabetes.
- Foundayo (orforglipron): a daily GLP-1 pill for weight management, approved in April 2026.
For weight management, Wegovy and Zepbound are approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. Semaglutide acts on one appetite hormone receptor, GLP-1; tirzepatide acts on two, GLP-1 and GIP.
Our Foundayo vs Zepbound guide compares a daily pill with a weekly shot.
How much semaglutide costs in Houston without insurance
The manufacturers sell directly to people paying cash, at the same price in Houston as anywhere else in the US. As of November 2026:
- Wegovy injection through NovoCare Pharmacy: $349 a month at every dose up to 2.4 mg. New patients can get the first two fills of the 0.25 mg and 0.5 mg starting doses for $199 each, an offer that runs through December 31, 2026.
- Wegovy pill: $149 a month for 1.5 mg, $199 for 4 mg, and $299 for 9 mg and 25 mg.
- Zepbound through LillyDirect, as vials or a KwikPen: $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg to 15 mg when each refill is completed within 45 days.
- Foundayo through LillyDirect: from $149 a month for the lowest dose.
Some Houston clinics and telehealth services sell a monthly program rather than the medicine alone, with visits and lab work folded in. Ask what the price includes, which product you will receive, and whether it is the FDA-approved brand. Money spent at the manufacturer's pharmacy this way usually does not count toward your insurance deductible.
Why many people in Texas end up paying cash
More than 1 in 3 adults in Texas has obesity: 36.1 percent in 2025, according to CDC survey data. Even so, Texas Medicaid does not cover GLP-1 medicines for weight loss, according to KFF's January 2026 review of state Medicaid programs. Many employer and Marketplace plans either exclude weight loss medicines or approve them only with prior authorization and a BMI cutoff.
A diagnosis can change the answer. A plan that refuses semaglutide for weight loss may still cover Ozempic or Mounjaro for type 2 diabetes, or Zepbound for moderate to severe sleep apnea. Ask your plan which diagnosis and paperwork it accepts before your prescriber sends anything.
If you have Medicare with a Part D plan, the temporary Medicare GLP-1 Bridge covers Wegovy, the Zepbound KwikPen and Foundayo for weight loss at $50 a month from July 1, 2026, through December 31, 2027. It is open to people with a BMI of 35 or higher. A lower BMI can qualify with certain conditions: 30 or higher with heart failure, uncontrolled high blood pressure or kidney disease, and 27 or higher with prediabetes or a past heart attack, stroke or peripheral artery disease. Your prescriber requests the prior authorization.
Compounded semaglutide: what the FDA says
During the shortages, compounding pharmacies made their own versions of semaglutide and tirzepatide, and some clinics and online services still sell them. The FDA declared the tirzepatide shortage over in December 2024 and the semaglutide shortage over in February 2025. In February 2026 it announced steps to restrict compounded GLP-1 products that are mass-marketed as alternatives to approved drugs.
Compounded drugs are not FDA-approved, so no one checks their quality, safety or effectiveness before they are sold. The FDA has received complaints about products that arrived warm, found fake products with false labels, and received reports of side effects, some needing hospital care, linked to dosing mistakes. Its advice is to use a compounded drug only when an approved product cannot meet your needs, to get a prescription, and to fill it at a state-licensed pharmacy. Products sold online as "research peptides" or "for research use only" are not meant for people at all.
Clinical studies in Houston if you cannot get or afford a prescription
Houston is one of the busiest cities in the country for diabetes, fatty liver and obesity research; our Houston clinical trials guide explains why. In a study, the medicine being tested, study visits and study-related tests are typically provided at no cost, and many studies reimburse travel. Each study has its own criteria, so the right one depends on your situation. You can also browse all weight loss clinical trials by location.
Overweight with prediabetes, BMI 25 to 29.9
This group has the fewest approved options: below the BMI line for most weight loss prescriptions, but with blood tests already moving the wrong way. A phase 3 study of orforglipron, the medicine in Foundayo, is enrolling at a site in Houston. It asks whether a daily pill at this earlier stage delays obesity-related conditions, such as type 2 diabetes, or progression to obesity over two years.
- Who it is for: adults with a BMI of 25 to 29.9, a waist at least half their height, at least one early warning sign (prediabetes, borderline blood pressure or borderline cholesterol), and at least one past attempt to lose weight with diet and exercise.
- Who it is not for: people with any type of diabetes, a diagnosis of high blood pressure or high cholesterol, a BMI of 30 or higher now or in the past, or a weight loss medicine in the past six months.
- How it works: every group takes orforglipron for at least part of the study, and some participants also take a placebo for part of it. Neither you nor the study team knows which you are taking during that time.
Our guide to prediabetes medication explains why this group is underserved. See the orforglipron study.
Fatty liver with scarring
Fatty liver disease is more common among Hispanic adults, and 44 percent of Houston residents are Hispanic, according to the Census Bureau. In a national study of more than 5,500 US adults, it affected 47 percent of Hispanic adults, compared with 40 percent of adults in other groups. It often causes no symptoms until scarring has built up.
If a scan has shown fat in your liver and some scarring, SYNERGY-Outcomes is enrolling at a site in Houston. It is a large study, with about 4,500 adults in total, and it tests whether tirzepatide or retatrutide can prevent serious liver problems compared with placebo over about four years. Tirzepatide is approved as Zepbound and Mounjaro, but not for this purpose; retatrutide is not approved at all.
- Who it is for: adults with liver fat of 8 percent or more, a FibroScan stiffness reading from 10 to just under 20 kPa, and a BMI of 25 or higher. People with type 2 diabetes can join if their A1C is 10 percent or lower.
- Who it is not for: people with type 1 diabetes, another liver disease, past serious liver complications, or a weight loss of more than 11 pounds in the three months before screening.
- After the main study: participants can choose a two-year extension in which everyone receives tirzepatide or retatrutide.
Our guide to FibroScan results explains the numbers. See SYNERGY-Outcomes.
Type 2 diabetes
Studies of investigational GLP-1 pills are enrolling in Houston for adults with type 2 diabetes and an A1C between 7 and 10.5 percent. Check if you qualify for these diabetes studies. Separate studies for adults who take daily insulin, or who have heart disease, are listed on our Houston clinical trials page.
Sleep apnea when CPAP has not worked
Studies for adults with obstructive sleep apnea and a BMI of 27 or higher who could not tolerate CPAP are enrolling in Houston. See the sleep apnea studies. Our guides cover CPAP alternatives and Zepbound for sleep apnea.
Most of these studies compare the medicine with a placebo for at least part of the time, which our guide to placebo-controlled trials explains. Your safety comes first, but no study is risk-free. An independent review board approves and oversees every study, you can leave at any point, and nothing starts until you have read and signed the informed consent form.
Common questions
How much does semaglutide cost in Houston without insurance? The same as anywhere in the US when you buy from the manufacturer. As of November 2026, Wegovy injections cost $349 a month through NovoCare Pharmacy after two introductory fills at $199, and the Wegovy pill costs $149 to $299 depending on the dose. A clinic program costs more if it bundles visits and lab work.
Does Texas Medicaid cover Wegovy or Zepbound for weight loss? No. As of January 2026, Texas Medicaid does not cover GLP-1 medicines for weight loss, according to KFF.
What is the difference between semaglutide and tirzepatide? Semaglutide (Wegovy, Ozempic) acts on the GLP-1 receptor. Tirzepatide (Zepbound, Mounjaro) acts on two receptors, GLP-1 and GIP. Which suits you depends on your health, your coverage and how you tolerate it, which is a conversation for you and your prescriber.
Can I get a weight loss medicine if my BMI is under 30? Wegovy and Zepbound are approved for a BMI of 27 or higher if you also have a weight-related condition. Below that, no weight loss medicine is approved, but a study of orforglipron in Houston is enrolling adults with a BMI of 25 to 29.9 and prediabetes or a similar early warning sign.
Is compounded semaglutide the same as Wegovy? No. Compounded versions are not FDA-approved, and the FDA does not check their quality, safety or effectiveness. The FDA has said they cannot be marketed as generic versions of approved drugs.
Are there GLP-1 studies in Houston? Yes. A study of orforglipron, a GLP-1 pill, is enrolling adults with a BMI of 25 to 29.9 and prediabetes at a Houston site, and studies of investigational GLP-1 pills for type 2 diabetes are also open in the city.
Do weight loss study participants get paid? Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.
